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Aromatase is the product of the CYP19 gene, a member of the
P450 superfamily of genes. It catalyses the rate-limiting step in
oestrogen biosynthesis, the conversion of C19 androgenic steroids
to the corresponding oestrogen, a reaction termed aromatization
since it converts the D4-3-one A-ring of the androgen to the
phenolic A-ring of oestrogen (Simpson et al, 1997). Several
studies have demonstrated measurable levels of aromatase mRNA
and enzyme activity in breast cancer tissues (Brodie et al, 1997;
Santner et al, 1997). As a result of in situ oestrogen production
by aromatase, breast tumour oestrogen concentrations remain
high, even in post-menopausal women (Miller and Forrest, 1976).
Aromatase activity in tumours or surrounding tissue may play a
significant role in promoting tumour growth due to this local
production of oestrogen (Brodie et al, 1997; Sasano and Harada,
1998; Blankenstein et al, 1999), which has been demonstrated to
have potent mitogenic activity on breast cancer cells in vitro (Prall
et al, 1998). Indeed, the majority of breast tumours are oestrogen-
responsive (de Cupis and Favoni, 1997). Therefore, one promising
approach to breast cancer therapy is to reduce or eliminate
oestrogen production by aromatase. Several aromatase inhibitors
have been synthesized and are in clinical trials (Brodie et al, 1999).
Retinoids, which include natural vitamin A (retinol), its metabo-
lites and esters, and synthetic analogues, are among the most well-
studied agents in chemoprevention. A number of retinoids have
significant preventive activity in many in vivo experimental
systems against breast, skin, bladder, lung, and oral carcinogenesis
(Sankaranarayanan and Mathew, 1996). In clinical trials, several
retinoids have achieved significant activity in the reversal of head
and neck, skin and cervical premalignancy, and in the prevention
of secondary tumours associated with breast, head and neck, skin
and non-small cell lung cancers (Man, 1994; Lippman et al, 1995).
In particular, a synthetic analogue of retinoic acid, N-(4-hydrox-
yphenyl)retinamide (4-HPR), also known as fenretinide, has been
extensively studied, as it is less toxic at pharmacological doses in
humans than natural retinoids. 4-HPR has been shown to have
many biological activities in vitro and in vivo which may result in
a decrease in the development and progression of breast cancer. 4-
HPR has potent preventive effects in rodent mammary tumour
models (Crist et al, 1997; Moon and Constantinou, 1997).
Interestingly, 4-HPR has been found to accumulate preferentially
in breast tissue (Formelli et al, 1993). Based on its low toxicity
profile, it is currently being tested in a large breast cancer preven-
tion trial (Costa et al, 1994). A definitive mechanism by which 4-
HPR exerts its chemopreventive effect on mammary tumour
growth has not been identified; indeed, in vitro experiments
suggest that 4-HPR exerts multifaceted effects on several path-
ways important to carcinogenesis and tumour progression,
including suppression of cell growth (Marth et al, 1985), induction
of apoptosis (Wang and Phang, 1996), inhibition of telomerase
activity (Bednarek et al, 1999) and inhibition of insulin-like
growth factor-induced cell growth (Favoni et al, 1998).
Because of the importance of aromatase to the growth of breast
tumours, in the present study we have examined the effect of
4-HPR on aromatase activity and expression. In order to study the
direct effect of 4-HPR on aromatase activity, we have used the
microsomal fraction isolated from JEG-3 human choriocarcinoma
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cellular aromatase activity and expression, we used the MCF-7
human breast cancer cells, which have been extensively used in
aromatase studies (Yano et al, 1995; Zhou et al, 1996). We report,
for the first time, that 4-HPR inhibits microsomal and cellular
aromatase activity, and inhibits the expression of aromatase
mRNA induced by cAMP.
MATERIALS AND METHODS
Materials
Unless otherwise noted, all reagents were from Sigma (St. Louis,
MO, USA). 4-HPR was dissolved in dimethylsulphoxide (DMSO)
at a concentration of 100 mM, aliquoted, and stored at –20°C. All
culture media components and trypsin/EDTA were from BioFluids
(Rockville, MD, USA).
Cell culture
JEG-3 human choriocarcinoma cells and MCF-7 human breast
carcinoma cells were purchased from the American Type Culture
Collection (Rockville, MD, USA). JEG-3 cells were maintained in
Eagle’s minimum essential medium with non-essential amino
acids, supplemented with 10% foetal bovine serum, and 2 mM
glutamine. MCF-7 cells were grown in RPMI 1640 supplemented
with 10% foetal bovine serum and 2 mM glutamine. Both cell
lines were passed weekly using 0.05% trypsin, 0.02% EDTA.
Microsomal preparation
JEG-3 cells were grown to confluence in 175 cm2 culture flasks.
The cells were trypsinized and pelleted by centrifugation, and the
pellet resuspended with phosphate-buffered saline (PBS) and
repelleted. The cell pellet was resuspended in 10 mM Tris-
HCl, pH 7.5, containing 0.25 M sucrose and protease inhibitors
(100 mg ml–1 phenylmethysulphonyl fluoride, 300 mg ml–1 EDTA,
0.5 mg ml–1 leupeptin, 0.5 mg ml–1 aprotinin and 0.7 mg ml–1
Pepstatin A). The cells were sonicated for 30 s on ice with a
Branson sonifer, setting 2. The sonicate was then subjected to
centrifugation at 10 000 g, 4°C, for 10 min to remove cellular
debris. The supernatant was subjected to centrifugation at
500 000 g, 4°C, for 15 min. The supernatant was removed and the
microsomal pellet was resuspended in the above buffer. Protein
was measured by the method of Bradford (1976) using bovine
serum albumin as a standard. Microsomes were aliquoted and
stored at –70°C.
Measurement of microsomal aromatase activity
Microsomal aromatase activity was measured by the 3H2O release
method as described by Choate and Resko (1996). This assay
measures the amount of 3H2O formed during the conversion of
androstenedione to estrone by aromatase. Briefly, 10 mg of JEG-3
microsomes were incubated with DMSO (control) or 4-HPR for
1 h at 37°C in 275 ml of PBS, pH 7.5, with 1 mM NADPH and
25 nM [1b-3H(N)]-androst-4-ene-3,17-dione (NEN, Boston, MA,
USA). The reaction was terminated by the addition of 75 ml of
50% trichloroacetic acid. This was subjected to centrifugation at
15 000 g, 4°C, for 15 min. The supernatant (275 ml) was removed
and 80 ml of 10% activated charcoal and 45 ml H2O was added.
This was vortexed gently and incubated at room temperature for
30 min. It was then subjected to centrifugation at 15 000 g, 4°C,
for 15 min. Radioactivity released as 3H2O was determined by
scintillation counting of 100 ml of the supernatant in Aquasol scin-
tillation fluid (Beckman, Palo Alto, CA, USA).
To determine the mechanism of inhibition, microsomal
aromatase activity was determined as described above in the
presence of different concentrations of [1 b-3H(N)]-androst-4-
ene-3, 17-dione with or without 4-HPR and a double-reciprocal
(Lineweaver–Burke) plot was generated.
Measurement of cellular aromatase activity
The amount of aromatase activity in intact MCF-7 cells was
measured as described in Shimodaria et al (1996). Confluent
MCF-7 cells in six-well culture plates were incubated at 37°C for
24 h in 1 ml of growth medium containing 25 nM [1 b-3H(N)]-
androst-4-ene-3,17-dione with or without 1 mM dibutryl-cyclic
AMP (cAMP) in the presence of DMSO (control) or 4-HPR. The
medium was then removed and 250 ml of activated charcoal was
added. This was incubated for 30 min at room temperature and
subjected to centrifugation at 15 000 g, 4°C, for 15 min. 625 ml
was used for scintillation counting as described above.
Measurement of aromatase mRNA
The amount of aromatase mRNA was determined by semi-quanti-
tative reverse transcription-polymerase chain reaction (RT-PCR).
Confluent MCF-7 cells in six-well culture plates were incubated at
37°C for 24 h in 1 ml of growth medium with or without 1 mM
cAMP in the presence of DMSO (control) or 4-HPR. Following
incubation, the cells were washed with PBS and total RNA was
isolated using Trizol reagent (Life Technologies, Gaithersburg,
MD, USA) as directed. cDNA was synthesized from 10 mg of total
RNA using a RT-PCR kit from Stratagene (La Jolla, CA, USA)
as instructed. PCR was performed using the aromatase primer
sequences and method of Zhou et al (1990), in the presence of
1.5 mCi of [32P]dATP (NEN). PCR was also run using primers for
glucose-3-phosphate dehydrogenase (G-3-PDH; Clonetech, Palo
Alto, CA, USA) as directed. The optimum cycle number that fell
within the exponential range of response for aromatase (25 cycles)
and G-3-PDH (19 cycles) was used. Following PCR, 5 ml of high-
density buffer (Novex, San Diego, CA, USA) was added to the
samples, and they were subjected to electrophoresis on a 10% tris-
borate EDTA gel (Novex) in 13 tris-borate EDTA buffer (Novex)
for 1.5 h at 125 V. The gel was then dried and visualized by phos-
phoimaging using a Bio-Rad GS-363 phosphoimager (Hercules,
CA, USA).
Statistical analysis
Statistical analysis was performed using one-way analysis of
variance (ANOVA), followed by the Fischer test. A P-value of
<0.05 was considered to be significant.
RESULTS
Effect of 4-HPR on microsomal aromatase activity
Microsomes isolated from JEG-3 human placental cancer cells
were used to determine the direct effect of 4-HPR on aromatase
activity. Incubation of 10 mg microsomes with 25 nM of the
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the co-factor NAPDH for 1 h resulted in a specific activity of
39.3 ± 1.7 pmoles mg–1 h–1. Addition of 4-HPR to the reaction
caused a dose-dependent decrease in aromatase activity, with a
1 mM concentration resulting in a 50% decrease in activity (IC50)
as compared to controls (Figure 1).
The inhibition of microsomal aromatase activity by increasing
concentrations of 4-HPR in the presence of different substrate
concentrations was also measured and the results were analysed
by double-reciprocal (Lineweaver–Burke) plot. As shown in
Figure 2, there was a dose-dependent increase in the Km of the
substrate in the presence of 4-HPR. The Vmax of the enzyme
reaction decreased in the presence of 4-HPR.
Effect of 4-HPR on cellular aromatase activity
When MCF-7 cells were incubated with the aromatase substrate
[1b-3H(N)]-androst-4-ene-3,17-dione for 24 h, we observed a
specific activity of 5.957 ± 0.399 fmoles h–1 million cells–1. Co-
incubation of the cells with 4-HPR resulted in a dose-dependent
decrease in aromatase activity (Figure 3). Treatment of the cells
with cAMP, a known inducer of aromatase expression, resulted in
an approximately 2-fold increase in specific activity. This was also
inhibited in the presence of 4-HPR in a dose-dependent manner
(Figure 3).
Effect of 4-HPR on aromatase mRNA
The amount of aromatase mRNA in MCF-7 cells was measured by
semi-quantitative RT-PCR. As seen in Figure 4, treatment of MCF-
7 cells with 4-HPR for 24 h had no effect on the basal level of
aromatase. Treatment of cells with cAMP for 24 h resulted in an
approximately 2-fold increase in aromatase mRNA. This increase
was completely abolished in cells co-incubated with 4-HPR.
4-HPR inhibits aromatase activity in MCF-7 cells 335
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Figure 1 Effect of 4-HPR on microsomal aromatase activity. 10 mg of
microsomes isolated from JEG-3 cells were incubated with 25 nM [1b-3H(N)]-
androst-4-ene-3,17-dione and 1 mM NADPH for 1 h and the amount of 3H2O
released was measured as described. Each point represents the mean of
four determinations ± standard error (SE). There was a statistically significant
decrease in aromatase activity at all 4-HPR concentrations tested (P < 0.05)
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Figure 2 Effect of 4-HPR on microsomal aromatase activity in the presence
of different substrate concentrations. 10 mg of JEG-3 microsomes were
incubated with NADPH and the indicated concentrations of [1b-3H(N)]-
androst-4-ene-3,17-dione in the presence of 0 (squares), 1 (diamonds),
2.5 (circles), or 5 (triangles) mM 4-HPR. Aromatase activity was measured as
described and the results were plotted as a double-reciprocal
(Lineweaver–Burke) plot
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Figure 3 Effect of 4-HPR on aromatase activity in MCF-7 cells in the
absence or presence of cAMP. MCF-7 cells were incubated for 24 h with
25 nM substrate and the indicated concentrations of 4-HPR with or without
1 mM cAMP. Aromatase activity was determined as described. Each bar
represents the mean of three determinations ± SE. There was a significant
decrease in aromatase activity in cells treated with either concentration of
4-HPR (P < 0.05)DISCUSSION
Despite the established chemopreventive effect of 4-HPR towards
mammary tumorigenesis, and the pivotal role of aromatase in the
growth of breast tumours, the effect of 4-HPR on the activity of
aromatase has not, to our knowledge, been studied. As a source of
aromatase activity, we isolated microsomes from JEG-3 human
choriocarcinoma cells and examined the effect of 4-HPR on
aromatase activity. As shown in Figure 1, 4-HPR inhibits micro-
somal aromatase activity in a dose-dependent manner, with an IC50
of 1 mM. The mechanism by which 4-HPR inhibits aromatase
activity appears to be multifactorial. Using Lineweaver–Burke
analysis of microsomal aromatase activity to determine the
kinetics of inhibition, we found that 4-HPR causes an increase in
the Km of the substrate, indicating that 4-HPR competes with the
substrate at the substrate binding site (Figure 2). However, the Vmax
of the reaction is decreased in the presence of 4-HPR, indicating
that non-competitive inhibition is also at work. Thus, the inhibi-
tion of aromatase activity by 4-HPR is complex.
Because aromatase is overexpressed in breast cancer tissue, the
effect of aromatase inhibitors in breast cancer cells is of particular
interest. We therefore examined the effects of 4-HPR on aromatase
activity in MCF-7 human breast cancer cells, an oestrogen-
receptor-positive cell line that has been extensively used in
aromatase studies (Yano et al, 1995; Zhou et al, 1996). Although
these cells did not possess sufficient aromatase to easily detect
activity in microsomal preparations, activity in intact cells is
measurable with a longer incubation time. As shown in Figure 3,
4-HPR caused a dose-dependent inhibition of both basal and
cAMP-induced aromatase activity in MCF-7 cells. Although not
as potent an inhibitor of cellular aromatase as some of the
recently synthesized substrate analogs of aromatase, which inhibit
aromatase activity at nanomolar concentrations (Brueggemeier
and Katlic, 1990; Miller, 1996; Yue and Brodie, 1997), 4-HPR has
been shown to accumulate preferentially in the breast, where
concentrations reach the micromolar range (Formelli et al, 1989).
Thus, the inhibition of aromatase activity demonstrated here
occurs at pharmacologically relevant doses.
cAMP activates transcription of CYP19, which encodes
aromatase, and contains cAMP-responsive elements (Zhao et al,
1996; Zhou et al, 1996). Although the results of the microsomal
assay (Figures 1 and 2) indicate that direct enzyme inhibition can
account for the decrease in aromatase activity in MCF-7 cells, the
inhibition of cAMP-induced cellular aromatase activity by 4-HPR
demonstrated in Figure 3 may also be the result of modulation of
aromatase expression. To test this possibility, we measured the
level of aromatase mRNA expression by RT-PCR. As shown in
Figure 4, aromatase mRNA is expressed in untreated MCF-7 cells
(control). Incubation with 4-HPR did not alter aromatase mRNA,
indicating that the inhibition of aromatase activity by 4-HPR in
untreated cells shown in Figure 3 is likely the result of direct inhi-
bition of the enzyme. Treatment of the cells with cAMP caused an
increase in the expression of aromatase mRNA which was
completely blocked in the presence of 4-HPR. The inhibition of
aromatase activity in intact MCF-7 cells treated with cAMP there-
fore results from both direct inhibition and an inhibition of
aromatase expression. Since cAMP increases aromatase expres-
sion by activating aromatase transcription, this result suggests that
4-HPR may interfere with aromatase transcription, but further
experiments are necessary to definitively establish this.
These results suggest that part of the established chemopreven-
tive activity of 4-HPR towards mammary tumourigenesis may be
the result of its effects on aromatase activity and expression. The
effects of natural retinoids on aromatase are currently under study.
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